Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience

Autor: Francesca Comito, Maria Cristina Morelli, Andrea Ardizzoni, Francesco Gelsomino, Giuseppe Lamberti, Vincenzo Di Nunno, Giovanni Vitale, Francesco Massari
Přispěvatelé: Vitale G., Lamberti G., Comito F., Di Nunno V., Massari F., Morelli M.C., Ardizzoni A., Gelsomino F.
Rok vydání: 2020
Předmět:
0301 basic medicine
Lung Neoplasms
anti-programmed cell death-ligand 1
medicine.drug_class
Digestive System Diseases
Programmed Cell Death 1 Receptor
Clinical Biochemistry
Cell
immune checkpoint inhibitor
Antibodies
Monoclonal
Humanized
Monoclonal antibody
hepatiti
B7-H1 Antigen
immune-related liver disease
Programmed cell death ligand 1
03 medical and health sciences
0302 clinical medicine
Immune system
Programmed cell death 1
Drug Discovery
medicine
Humans
Immune Checkpoint Inhibitors
Melanoma
large-duct cholangiti
Pharmacology
Hepatitis
small-duct cholangitis
biology
cholecystiti
business.industry
Antibodies
Monoclonal
Ligand (biochemistry)
medicine.disease
Nivolumab
Anti-programmed cell death-1
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
Cancer research
biology.protein
business
Zdroj: Expert Opinion on Biological Therapy. 20:1047-1059
ISSN: 1744-7682
1471-2598
DOI: 10.1080/14712598.2020.1762562
Popis: Introduction: Monoclonal antibodies directed against programmed cell death-1 (anti-PD-1) and its ligand (anti-PD-L1) showed a significant efficacy among different immunogenic metastatic tumors such as melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC). Between immune-related adverse events (irAEs) dependent on immune checkpoint inhibitors (ICPIs), immune-related liver diseases are uncommon and a definitive diagnosis is not always feasible. Areas covered: We revised data from phase II/III clinical trials and real-world retrospective analyses on liver-related adverse events induced by anti-PD-1 (nivolumab/pembrolizumab) and anti-PD-L1 (atezolizumab) in advanced cancer populations (melanoma, NSCLC and RCC). Furthermore, we described clinical-pathological patterns of immune-related liver diseases in real-life. Expert opinion: Use of anti-PD-1 and anti-PD-L1 led to a paradigm shift in the management of patients with melanoma, NSCLC and RCC. IrAEs can occur potentially in any tissue, leading to discontinuation of ICPIs, at least in a small proportion of these patients, and to a negative impact on their prognosis. Hepatobiliary immune-related adverse events are underestimated due to inappropriate monitoring. Development of novel diagnostic and therapeutic strategies for cancer patients receiving ICPIs as well as the identification of predictive biomarkers of liver injury could allow a better patients’ selection and improve clinical outcomes of immune-related liver diseases.
Databáze: OpenAIRE
Externí odkaz: